Mutagenesis and Carcinogenesis
This record is part of
a dataset collected by the EU Commission in June-September 2018
. Some of these links will therefore die out with time.
Please see the
overview of courses maintained by ETPLAS
or contact Norecopa for more information.
Owner/Developer: Safety Sciences for Medicines (safe sci med)
Country: |
Germany |
---|---|
Languages: |
English |
Url: |
https://ssm.afww.uni-konstanz.de/courses/safescimet-course-35-mutagenesis-and-carcinogenesis |
Created: |
25 September 2017 |
Locations: |
Germany |
City: |
Konstanz |
Description: | Course Objectives Besides heredity and environmental factors, chemical exposure is responsible for approximately two thirds to three quarters of all cancers. The development of new chemical compounds holds the potential risk of harmful mutagenic and/or carcinogenic effects to humans. Minimising these risks during drug development requires appropriate experimentation and expert knowledge whose basic principles will be delivered with this course. Special emphasis will be given to the biology of cancer formation, the identification of mutagens and carcinogens and their modes of action on the cellular, biochemical and molecular level. In silico methods prediction as well as animal test systems and tissue culture assays for carcinogenicity testing will be presented. Furthermore, the importance of responsibly estimating dose-dependent probabilities of mutagenic/carcinogenic effects (risk assessment) and the risk-benefit evaluation will be discussed. In case studies, participants will review and assess safety data for mutagenic and carcinogenic compounds. Key Subjects Covered by the Course - Overview on the biology of carcinogenesis - Principles of mutagenesis and carcinogenesis - Examples of the mutagenic/carcinogenic actions at the cellular, biochemical and molecular level - Experimental design for specific identification of mutagenic/carcinogenic compounds - Interpretation of dose-response curves - Extrapolation of animal findings and experimental data to human - Safety data reports, authority guidelines - Risk-benefit evaluation |
References: | https://ssm.afww.uni-konstanz.de/ |
Format: |
Hands-on training, Lecture |
Presence: |
Optional / Voluntary |
Access: |
Fee-based |
Content type: |
Theoretical, Practical |
Duration: |
90 hours |
Group size: |
20 |
Prerequisites: |
MSc in Live Sciences or equivalent |
Target audience: |
Students, Researchers, Regulators and policy-makers, Teachers and educators, Technicians, Scientific officers / Project managers |
Target sectors: |
Academia, Industry, Governmental bodies, Contract Research Organizations (CROs), SMEs |
Educational level: |
Continuing Professional Development, University (Master) |
3rs relevance: |
Replacement |
Topics covered: |
In vitro methods, Computational methods |
3rs coverage: |
Partial coverage (e.g. a module) |
Course level on animal species: |
Advanced course |
Learning outcome: |
Learning Outcomes On successful completion of the course, participants will understand basic principles in chemical mutagenesis and carinogenesis in a broader context, and will perform risk assessment and risk-benefit evaluations for mutagenic and/or carcinogenic compounds at an advanced level. More specifically, participants will be able to - understand key cellular and molecular alterations in carcinogenesis - identify and characterise mutagenic effects of chemical compounds - elucidate mechanisms of mutagenic and carcinogenic action at the cellular, biochemical and molecular level - review and assess safety data generated for a mutagenic/carcinogenic compound - estimate the probability of occurrence of mutagenic and/or carcinogenic effects (risk assessment) |
Accreditation body and/or authority that approved the education or training: |
ECTS |
Qualification received: |
3 ECTS credits |
Fant du det du lette etter?
Ja, jeg fant det! Nei, jeg fant det ikke!Takk for din tilbakemelding! Vær oppmerksom på at vi ikke kan kontakte deg hvis ikke du oppgir din epostadresse.
Hva lette du etter?
Gi oss gjerne en tilbakemelding slik at vi kan forbedre informasjonen på siden. På forhånd takk for hjelpen! Vennligst skriv inn din epostadresse hvis du vil ha et svar.
Kontakt oss gjerne på e-post hvis du har spørsmål.